Friday, 06 Dec 2019

You are here

Nintedanib May Benefit Systemic Sclerosis Related Interstitial Lung Disease

The NEJM reports a randomized placebo controlled trial of nintedanib, a tyrosine kinase inhibitor, in systemic sclerosis patients with interstitial lung disease (ILD) resulted in less pulmonary decline, but had no effect on other features of systemic sclerosis. 

Systemic sclerosis patients were enrolled if within 7 years of disase onset (non-Raynaud’s) and had high-resolution computed tomographic scan showing lung fibrosis affecting at least 10% of the lungs. Patients were randomized to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over 52 weeks. 

Among 576 patients, 52% had diffuse cutaneous systemic sclerosis, and 48.4% were on background mycophenolate.

The prime outcome was the adjusted annual rate of change in FVC change:

  • nintedanib group : −52.4 ml per year
  • placebo group: −93.3 ml per year (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P=0.04)

Other outcomes were not significant including the modified Rodnan skin score and the SGRQ at week 52.

Diarrhea, was much more common in those receiving nintedanib (75.7% vs 31.6%).

Nintedanib (Ofev) is currently FDA approved for use in idiopathic pulmonary fibrosis. It may have protective benefits in systemic sclerosis patients who develop ILD, but does not appear to otherwise benefit extrapulmonary disease progression in systemic sclerosis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

BMS and Celgene Merge as Amgen Buys Otezla

Bristol-Myers Squibb (BMS) has completed its $74 billion acquisition of Celgene. With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.

ACR 2019 – Best of the Plenary Sessions

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

New EMA Warnings for Tofacitinib in Patients at Risk for Clots

The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.

FDA Approves Ustekinumab for Ulcerative Colitis

Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.

Interleukin Targeted Biologics Increase Risks of Infection

A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.